Piramal Pharma approves grant of 56.3 lakh stock options
Piramal Pharma Limited's Nomination and Remuneration Committee approved the grant of 56,36,436 stock options under the 2022 ESOP plan on July 29, 2026. Priced at ₹10 per option, the grants feature distinct vesting schedules for domestic and US employees, with vesting periods spanning up to three years. The move complies with SEBI Listing Regulations and aims to align employee interests with long-term shareholder value.

*this image is generated using AI for illustrative purposes only.
Piramal Pharma Limited Piramal Pharma Limited has approved the grant of 56,36,436 stock options to its employees under the Employee Stock Option and Incentive Plan 2022. The Nomination and Remuneration Committee of the Board of Directors sanctioned the grants during its meeting held on July 29, 2026, in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The total number of equity shares covered by these options stands at 56,36,436. Each option carries an exercise price of ₹10 per option. This pricing structure is designed to provide employees with a fixed cost basis for acquiring shares, potentially offering upside participation if the market price exceeds the exercise price over the vesting period.
Vesting and Exercise Terms
The vesting schedule varies depending on the employee's location, specifically distinguishing between staff based outside the United States and those within the US. For all locations except the US, three alternative vesting structures apply:
| Vesting Tranche | Vesting Date | Exercisable Until | Applicable Structure |
|---|---|---|---|
| 1/3rd | July 29, 2027 | July 28, 2032 | Option A |
| 1/3rd | July 29, 2028 | July 28, 2033 | Option A |
| 1/3rd | July 29, 2029 | July 28, 2034 | Option A |
| 2/3rd | July 29, 2027 | July 28, 2032 | Option B |
| 1/3rd | July 29, 2028 | July 28, 2033 | Option B |
| 70% | July 29, 2027 | July 28, 2032 | Option C |
| 30% | July 29, 2028 | July 28, 2033 | Option C |
For employees located in the US, the vesting schedule is more accelerated, with all tranches becoming exercisable within a shorter window after vesting:
| Vesting Tranche | Vesting Date | Exercisable Until |
|---|---|---|
| 1/3rd | July 29, 2027 | March 15, 2028 |
| 1/3rd | July 29, 2028 | March 15, 2029 |
| 1/3rd | July 29, 2029 | March 15, 2030 |
Options can generally be exercised within five years commencing from the date of vesting of each tranche. However, for US-based employees, the exercise period is strictly limited to the dates mentioned in the schedule above.
Regulatory Compliance
The disclosure was made pursuant to Regulation 30 read with Schedule III to the SEBI Listing Regulations. The scheme is compliant with the SEBI (Share Based Employee Benefits) Regulations, 2021. Maneesh Sharma, Company Secretary & Compliance Officer, signed the filing submitted to both BSE Limited and the National Stock Exchange of India Limited on July 29, 2026.
Historical Stock Returns for Piramal Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.16% | +5.88% | +17.37% | +27.10% | -4.24% | +5.46% |
How might the dilution from 56.36 lakh new equity shares impact Piramal Pharma's earnings per share (EPS) and existing shareholder value over the next five years?
Given the low exercise price of ₹10, what is the estimated total share-based compensation expense this grant will add to the company's P&L in the upcoming fiscal years?
Will the accelerated vesting schedule for US-based employees signal a strategic push to retain talent in key Western markets amidst rising global pharmaceutical competition?


































